Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3718-3725

  Kesten, Suzanne R ^a   Heffner, Thomas G ^a   Johnson, Stephen J ^a   Pugsley, Thomas A ^a   Wright, Jonathan L ^a   Wise, Lawrence D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYL 4 [4 (2 PYRIMIDINYL) 1 PIPERAZINYLMETHYL]IMIDAZOLE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 7 [(2 PHENYLAMINOETHYLAMINO)METHYL]CHROMEN 2 ONE; CHROMEN 2 ONE; CLOZAPINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; SONEPIPRAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CHO CELL; DOPAMINERGIC SYSTEM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PSYCHOSIS; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOPYRANS; CHO CELLS; CRICETINAE; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG DESIGN; HUMANS; MICE; MOTOR ACTIVITY; PIPERAZINES; PROTEIN BINDING; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA; STARTLE REACTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033539161     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990266k     Document Type: Article

References (19)

1. Reynolds, G. P. Developments in the Drug Treatment of Schizophrenia. Trends Pharmacol. Sci. 1992, 13, 116-121.
2. Civelli, O.; Bunzow, J. R.; Grandy, D. K.; Zhou, Q.-Y.; Van Tol, H. H. M. Molecular Biology of the Dopamine Receptors. Eur. J. Pharmacol.-Mol. Pharmacol. Sect. 1991, 207, 277-286.
3. Seeman, P. Dopamine Receptors and the Dopamine Hypothesis of Schizophrenia. Synapse 1987, 1, 133.
4. Seeman, P. Dopamine Receptor Sequences: Therapeutic Levels of Neuroleptics Occupy D2 Receptors, Clozapine Occupies D4. Neuropsychopharmacology 1992, 7, 261-284.
5. Van Tol, H. H. M.; Bunzow, J. R.; Guan, H.-C.; Sunahara, R. K.; Seeman, P.; Niznik, H. B.; Civelli, O. Cloning of the Gene for a Human Dopamine D4 Receptor with High Affinity for the Antipyschotic Clozapine. Nature 1991, 350, 610-614.
6. Krupp, P.; Barnes, P. Clozapine-Associated Agranularcytosis: Risk and Aetiolgy. Br. J. Psychiatry 1992, 160 (Suppl. 17), 38-41.
7. Thurkauf, A.; Yuan, J.; Chen, X.; Wasley, J. W. F., Meade, R.; Woodruff, K. H.; Huston, K.; Ross, P. C. 1-Phenyl-3-(amino-methyl)pyrroles as Potential Antipsychotic Agents. Syntheses and Dopamine Receptor Binding. J. Med. Chem. 1996, 38, 4950-4952.
8. Kulagowski, J. J.; Broughton, H. B.; Curtis, N. R.; Mawer, I. M.; Ridgill, M. P.; Baker, R.; Emms, F.; Freedman, S. B.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C. I.; Leeson, P. D. 3-[[4-(4-Chlorophenyl)piperaziti-1-yl]methyl]-1H-pyrrolo[2,3-b]-pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D4 Receptor. J. Med. Chem. 1996, 39, 1941-1942.
9. Ten Brink, R. E.; Bergh, C. L.; Duncan, J. N.; Harris, D. W.; Huff, R. M.; Lahti, R. A.; Lawson, C. F.; Lutske, B. B.; Martin, I. J.; Rees, S. A.; Schlachter, S. K.; Sih, J. C.; Smith, M. W. (S) (-)-4-[4-[2-(Isochroman-1-yl)ethyl]piperazin-1-yl]benzene-sulfonamide, a Selective Dopamine D4 Antagonist. J. Med. Chem. 1998, 39, 2435-2437.
10. Kramer, M.; Lasr, B.; Zimbroff, D.; Hafez, D.; Alpert, M.; Allan, E.; Rotrosen, J.; McEvoy, J.; Kane, J.; Kronig, M.; Merideth, C.; Silva, J. A.; Ereshefsky, L.; Marder, S.; Wirshimg, W.; Conley, R.; Getson, A.; Chavez-Eng, C.; Cheng, H.; Reines, S. The Effects of a Selective D4 Receptor Antagonist (L-745,870) in Acutely Psychotic Schizophrenic Patients. Arch. Gen. Psychiatry 1997, 54, 567-572.
11. Jainamma, K. M.; Sethna, S. J. Indian Chem. Soc. 1973, 50, 790.
12. Poindexter, G. S.; Owens, D. A.; Dolan, P. L.; Woo, E. The Use of 2-Oxazolidinoles as Latent Aziridine Equivalents. J. Org. Chem. 1992, 57, 6257-6265.
13. Pugsley, T. A.; Davis, M. D.; Akunne, H. C.; MacKenzie, R. G.; Shih, Y. H.; Damsma, G.; Wikstrom, H.; Whetzel, S. Z.; Georgic, L. M.; Cooke, L. W.; Demattos, S. B.; Corbin, A. E.; Glase, S. A.; Wise, L. D.; Dykstra, D.; Heffner, T. G. Neurochemical and Functional Characterization of the Preferentially Selective Dopamine D3 Agonist PD 128907. J. Pharmacol. Exp. Ther. 1995, 275, 1355-1366.
14. Ohio, C. L.; Lajiness, M. E.; Huff, R. M. Activation of Heterologously Expressed D3 Dopamine Receptors: Comparison with D2 Dopamine Receptors. Mol. Pkarmacol. 1994, 45, 51-60.
15. Amt, J. Differential Effects of Classical and Newer Anti-psychotics on the Hypermotility Induced by Two Dose Levels of d-Amphetamine. Eur. J. Pharmacol. 1995, 283, 55-62.
16. McLean, J. R.; Parker, R. B.; Coughenour, L. L. Effect of Antipsychotics and Other Classes of Drugs on Spontaneous Locomotor Activity and Neurotoxicity in Mice. Pharmacol. Biochem. Behav. 1978, 8, 97-99.
17. Braff, D. L.; Stone, C.; Calloway, E.; Geyer, M.; Glick, I.; Bali, L. Prestimulus Effects on Human Startle Reflex in Normals and Schizophrenics. Psychophysiology 1978, 15, 339-393.
18. Mansbach, R. S.; Geyer, M. A.; Braff, D. L. Dopaminergic Stimulation Disrupts Sensiomotor Gating in the Rat. Psychopharmacology 1988, 94, 507-514.
19. Ellenbroek, B. A.; Peeters, B. W.; Honig, W. M.; Cools, A. R. The Paw Test: A Behavioral Paradigm for Differentiating between Classical and Atypical Neuroleptic Drugs. Psychopharmacology 1987, 93, 343-348.